摘要/Abstract

摘要： 钠-葡萄糖共转运蛋白2抑制剂（sodium-glucose cotransporter 2 inhibitor，SGLT2i）是一种新型降糖药，可降低2型糖尿病患者的全因死亡率，以及发生主要不良心脏事件和因心力衰竭而住院的风险。研究发现，除降糖作用外，SGLT2i还可通过降低心脏前后负荷、改善血流动力学、抗心肌纤维化、改变心脏能量供应等机制发挥心血管保护作用。该文对近年来有关SGLT2i的相关临床试验及机制进行综述，探讨SGLT2i对2型糖尿病患者的心血管保护作用。
关键词: 钠-葡萄糖共转运蛋白2抑制剂, 2型糖尿病, 心血管疾病, 恩格列净, 卡格列净, 达格列净
Abstract:
As a novel anti-diabetes drug, sodium-glucose cotransporter 2 inhibitor (SGLT2i) can decrease the all-cause mortality, the risk of major adverse cardiac event (MACE) and rate of heart failure hospitalization in patients with type 2 diabetes. Studies found that besides the function of glycemic control, SGLT2i could reduce the preload and afterload of heart, improve the hemodynamics, attenuate myocardial fibrosis and rejuvenate myocardial energetics. In this paper, clinical trials about SGLT2i in recent years and the mechanisms are reviewed to discuss the progress of the cardioprotection effect of SGLT2i on patients with type 2 diabetes.
Key words: sodium-glucose cotransporter 2 inhibitor, type 2 diabetes, cardiovascular disease, empagliflozin, canagliflozin, dapagliflozin


PDF全文下载地址:

点我下载PDF